Tidligere MCyR med imatinib sås hos henholdsvis 28% og 29% af patienterne i dasatinib - og imatinib- armen.
A prior MCyR to imatinib was achieved in 28% and 29% of the patients in the dasatinib and imatinib arms, respectively.